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This editorial refers to ‘TWEAK is a positive regulator of
cardiomyocyte proliferation’ by T. Novoyatleva et al., pp.
681–690, this issue.
Acute myocardial infarction and inherited cardiomyopathies, due to
extensive loss of cardiomyocytes, may progress towards heart
failure despite revascularization procedures and pharmacological
treatments. Initial studies supported the concept that bone marrow
cells may hold the promise of rebuilding the injured heart from its
component elements, offering a valid alternative to the ultimate
resort of heart transplantation.
1 However, stem cell biology turned
out to be considerably more complex than initially expected. Differ-
ent stem cell populations, including mesenchymal stem cells, adipose-
and amniotic ﬂuid-derived stem cells, and cardiac-resident stem cells
have been progressively characterized. It is also evident that growth
factor secretion from transplanted stem cells may activate angiogenic,
antiapoptotic, and antiﬁbrotic paracrine patterning, playing a major
role in cardiac repair.
2,3 Stem cell growth and differentiation may be
subjected to autocrine regulation by secreted growth factors or it
may be orchestrated in an intracrine fashion by growth regulatory
peptides acting within their cell of synthesis through nuclear receptors
and signaling.
4,5 On the basis of these intriguing dynamics, it is not sur-
prising that multiple randomized clinical trials with autologous bone
marrow cells in acute myocardial infarction yielded modest, transient,
or no improvement in cardiac performance.
6–9Indeed, cardiovascular
commitment and secretion of trophic mediators are extremely low-
yield processes in both adult and embryonic stem cells. To this end,
cell-based phenotypic- and pathway-speciﬁc screens of natural and
synthetic compounds are on the way to providing a number of mol-
ecules that can achieve selective control of stem cell growth and
differentiation.
3,10
A different approach in providing a source of new cardiomyocytes
may be based on the idea of coaxing adult cardiomyocytes to reenter
the cell cycle. Enabling proliferation in these cells may represent an
alternative area of inquiry in cardiac reparative/regenerative medicine
and may also involve a paradigm shift in the current view(s) of cardiac
cell therapy. Compelling evidence indicates that adult cardiomyocytes
still harbour signalling circuits capable of efﬁciently resuming their
proliferative potential,
11,12 suggesting that stem cells may not rep-
resent the only tool to afford a regenerative medicine for the heart.
Within this context, based on the ﬁnding that induction of cardiomyo-
cyte proliferation in vivo may promote heart regeneration, in this issue
of Cardiovascular Research, Novoyatleva et al.
13 aimed at investigating
the effects elicited by TNF-related weak inducer of apoptosis
(TWEAK) on postnatal rat cardiomyocytes. TWEAK, a member of
the TNF-a family regulates proliferation in multiple cell types includ-
ing liver oval cells, salivary epithelial cells, skeletal muscle myoblasts,
kidney mesangial cells, podocytes, and tubular cells.
14
TWEAK is produced as a type II transmembrane glycoprotein and
is processed into a 156-amino acid soluble cytokine. Its biological pro-
cesses involve inﬂammation, angiogenesis, and cell survival and are
mediated through the ﬁbroblast growth factor-inducible molecule
14 (FN14) receptor, a ﬁnely tuned, inducible receptor encompassing
multiple downstream signalling cascades.
14
Novoyatleva et al.
13 report that stimulation of neonatal rat cardio-
myocytes with TWEAK recombinant protein resulted in a remark-
able, dose-dependent increase in DNA synthesis. TWEAK also
increased the expression of the proliferative markers cyclin D2 and
Ki67, whereas down-regulating the cell cycle inhibitor p27KIP1. The
pro-mitotic action of TWEAK was further supported by the obser-
vation that it enhanced the number of H3P-positive cardiomyocytes.
Evidence that TWEAK led to effective cardiomyocyte division was
provided by the ﬁnding that the cytokine also increased the
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marker of the central spindle and the mid-body, and Troponin
I. Loss-of-function experiments using the ITEM-2 antibody (blocking
the interaction between TWEAK and FN14) or FN14 siRNA revealed
that re-induction of proliferation was dependent on FN14 signalling.
Assessment of the phosphorylated form of targeted kinases and the
use of speciﬁc kinase inhibitors indicated that the TWEAK/
FN14-mediated patterning involved the activation of ERK and PI3K
as well as inhibition of GSK-3b, which in turn led to stabilization
and accumulation of total b-catenin and accumulation of depho-
sphorylated b-catenin in the nucleus. TWEAK did not affect prolifer-
ation of adult rat cardiomyocytes. This different behaviour resulted
from progressive down-regulation of FN14 gene and protein
expression after birth. Accordingly, adenoviral expression of FN14
enabled efﬁcient induction of cell cycle reentry in adult cardiomyo-
cytes after TWEAK stimulation. To this end, overexpression of
FN14 receptor alone induced DNA synthesis in adult cardiomyocytes,
owing to the presence of endogenous TWEAK protein in these cells.
On the whole, these ﬁndings may have relevant biomedical impli-
cations in cardiac regenerative medicine. In fact, the clinical use of
stem cells will be hampered in the near future by a number of inter-
related challenges, including: (i) high-throughput bioprocess develop-
ment and improved downstream processing problems; (ii) signiﬁcant
modiﬁcation, improvement, and re-testing of current strategies of
stem cell culturing and cardiovascular commitment complying with
all standards of Good Manufacturing Practice (GMP); (iii) analytical
methodologies for control of GMP bioprocessing and differentiation
efﬁciencies. Therefore, the timing for cell culture and expansion
within a GMP setting will involve a substantial delay (several weeks)
in autologous stem cell transplantation after the acute phase of a
heart attack. On the contrary, efﬁcient induction of proliferation in
resident adult cardiomyocytes may represent a rapid, ﬁrst aid to
rescue a failing heart. Direct functional approaches should then be
designed in experimental models of myocardial infarction or failure
to assess whether activation of TWEAK signalling in vivo may contrib-
ute to replenish lost cardiomyocytes and improve myocardial per-
formance. Further efforts should also attempt to identify chemical
compounds that functionally replace viral vector-mediated overex-
pression of FN14 in adult cardiomyocytes.
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